Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
High Dose
100%
Randomized Trial
100%
Clinical High Risk
100%
R-CHOP
100%
Sequential Chemotherapy
100%
Rituximab
85%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
42%
Intent-to-treat
28%
Event-free Survival
28%
Treatment-related Mortality
28%
Overall Survival
14%
Prednisone
14%
Complete Response
14%
Clinical Response
14%
Chemotherapy
14%
Prognostic Score
14%
Disease-free Survival
14%
Am(III)
14%
Partial Response
14%
Progression-free Survival
14%
Doxorubicin
14%
No Response
14%
High-dose Chemotherapy
14%
International Prognostic Index
14%
Early Treatment
14%
Hematotoxicity
14%
Randomized Phase III Trial
14%
P-12
14%
Infectious Complications
14%
R-CHOP-14
14%
Rituximab Plus Cyclophosphamide
14%
Medicine and Dentistry
Drug Megadose
100%
Rituximab
100%
Diffuse Large B-Cell Lymphoma
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Arm
57%
Autologous Stem Cell Transplantation
42%
Intention-to-Treat Analysis
28%
Event Free Survival
28%
Cyclophosphamide
14%
Prednisone
14%
Overall Survival
14%
Disease Free Survival
14%
Progression Free Survival
14%
International Prognostic Index
14%
Doxorubicin
14%
Vincristine
14%
High Dose Chemotherapy
14%
Infectious Complication
14%
Phase III Trials
14%
Immunology and Microbiology
B Cell
100%
Drug Megadose
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Rituximab
87%
Arm
50%
Autologous Stem Cell Transplantation
37%
Event Free Survival
25%
Prednisone
12%
Cyclophosphamide
12%
Disease Free Survival
12%
Overall Survival
12%
Progression Free Survival
12%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Diffuse Large B Cell Lymphoma
100%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
100%
Rituximab
87%
Event Free Survival
25%
Cyclophosphamide
12%
Prednisone
12%
Overall Survival
12%
Disease Free Survival
12%
High Dose Chemotherapy
12%
Progression Free Survival
12%
Doxorubicin
12%
Vincristine
12%
Infectious Complication
12%
Phase III Trials
12%
Agricultural and Biological Sciences
B Cell
100%
Rituximab
100%
Autologous Stem Cell Transplantation
42%
Vincristine
14%
Prednisone
14%